Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.51 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.51 |
| ▸ | GPR39 | O43194 | 3/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.46 |
| ▸ | MERTK | Q12866 | 1/20 | 0.46 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
| ▸ | FABP1 | P07148 | 1/20 | 0.45 |
| ▸ | FABP6 | P51161 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | PAK4 | O96013 | 1/20 | 0.43 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL797462 | 0.88 | GPR39 (0.60) | HRH4GPR39GRIN2BCXCR4FABP1 | |
| SCHEMBL17700541 | 0.85 | GPR39 (0.54) | GPR39GRIN2BCXCR4FABP1FABP6 | |
| SCHEMBL5879518 | 0.84 | CYP1A2 (0.47) | AXLFLT3TYRO3MERTKGAS6 | |
| SCHEMBL17700175 | 0.83 | GPR39 (0.56) | GPR39GRIN2BCXCR4FABP1FABP6 | |
| SCHEMBL4522025 | 0.83 | CXCR4 (0.49) | HRH4GPR39GRIN2BCXCR4FABP1 | |
| Hydrochloric Acid SCHEMBL30585800 | 0.82 | CXCR4 (0.47) | HRH4GPR39GRIN2BCXCR4FABP1 | |
| Hydrochloric Acid SCHEMBL21641198 | 0.82 | CXCR4 (0.47) | HRH4GPR39GRIN2BCXCR4FABP1 | |
| SCHEMBL30794445 | 0.81 | HIF1A (0.51) | GPR39GRIN2BCXCR4FABP1FABP6 | |
| SCHEMBL17700171 | 0.81 | HIF1A (0.51) | GPR39GRIN2BCXCR4FABP1FABP6 | |
| SCHEMBL761678 | 0.80 | HRH4 (0.54) | HRH4IRAK4GRIN2BAXLFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349839-B2 | Inhibitors of HIV replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-08 | — | — | US | disclosed |
| WO-2011079274-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals, LLC (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2010115264-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261714-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-7763621-B2 | Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS (FR) | 2010-07-27 | — | — | US | disclosed |
| US-7763621-B2 | Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS (FR) | 2010-07-27 | — | — | US | disclosed |
| US-7582640-B2 | Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS (FR) | 2009-09-01 | — | — | US | disclosed |
| US-7582640-B2 | Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS (FR) | 2009-09-01 | — | — | US | disclosed |
| EP-2070914-A1 | New antagonist derivatives of the vitronectin receiver, method for preparing same, application of same as medicine and pharmaceutical compositions containing them | Galapagos SAS (FR) | 2009-06-17 | — | — | EP | disclosed |
| US-20090149476-A1 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS | 2009-06-11 | — | — | US | disclosed |
| WO-2003066624-A1 | PYRIMIDINONESULFAMOYLUREAS AS INTEGRIN LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2003-08-14 | — | — | WO | disclosed |
| EP-1286673-A2 | LIGANDS OF INTEGRIN RECEPTORS | Basf Aktiengesellschaft (DE) | 2003-03-05 | — | — | EP | disclosed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | disclosed |
| CN-1374960-A | novel integrin receptor antagonists | BASF AG (DE) | 2002-10-16 | — | — | CN | disclosed |
| EP-1216230-A2 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | Amgen Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| CN-1353706-A | Integrin receptor ligands | BASF AG (DE) | 2002-06-12 | — | — | CN | disclosed |
| EP-1171435-A2 | PYRIMIDINE-2-ONE DERIVATIVES AS INTEGRIN RECEPTOR LIGANDS | BASF AKTIENGESELLSCHAFT (DE) | 2002-01-16 | — | — | EP | disclosed |
| WO-2001093840-A2 | LIGANDS OF INTEGRIN RECEPTORS | BASF AG (DE) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001023357-A2 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2001-04-05 | — | — | WO | disclosed |
| WO-2000061551-A2 | PYRIMIDINE-2-ONE DERIVATIVES AS INTEGRIN RECEPTOR LIGANDS | BASF AKTIENGESELLSCHAFT (DE) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149476-A1 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | ADGRF1, C5AR2, ADGRE5 | HRH4 177/4885IRAK4 1418/4885GPR39 103/4885 |
| US-20100261714-A1 | INHIBITORS OF HIV REPLICATION | RTF2, POLR1A, REV1 | HRH4 1546/4885IRAK4 2365/4885GPR39 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.